Financial Review: QHSLab (OTCMKTS:USAQ) versus Atossa Genetics (NASDAQ:ATOS)

Atossa Genetics (NASDAQ:ATOS) and QHSLab (OTCMKTS:USAQ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Volatility & Risk

Atossa Genetics has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, QHSLab has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500.

Valuation and Earnings

This table compares Atossa Genetics and QHSLab”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77 million	($3.21)	-0.75
QHSLab	$2.69 million	0.99	$460,000.00	$0.03	7.90

QHSLab has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than QHSLab, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

12.7% of Atossa Genetics shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by company insiders. Comparatively, 74.2% of QHSLab shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Atossa Genetics and QHSLab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-84.91%	-72.36%
QHSLab	15.60%	-27.74%	-6.98%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Atossa Genetics and QHSLab, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2	0	3	0	2.20
QHSLab	0	0	0	0	0.00

Atossa Genetics currently has a consensus target price of $20.33, indicating a potential upside of 747.22%. Given Atossa Genetics’ stronger consensus rating and higher possible upside, research analysts plainly believe Atossa Genetics is more favorable than QHSLab.

Summary

QHSLab beats Atossa Genetics on 8 of the 13 factors compared between the two stocks.

About Atossa Genetics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

About QHSLab

QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. The company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. QHSLab, Inc. was incorporated in 1983 and is based in West Palm Beach, Florida.